melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling
Melior Discovery
home
Therapeutic Areas
Safety Assessment
 

theraTRACE

Melior Pharmaceuticals

              

 

             

 

                 

melior melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling

Melior Discovery metabolic

Oral Glucose Tolerance Test
Type II diabetes is characterized by high blood glucose levels in the presence of normal amounts of insulin. There are many animal models of type II diabetes involve administering high levels of glucose and measuring blood glucose levels and the ability of the experimental animal to maintain glucose homeostasis over time. Several pharmacological structural classes can effectively regulate this hyperglycemic response including sulfonylureas, thiazoladinediones (PPARγ agonists; glitazones) and Metformin (glucophage). These drug classes are also clinically approved for use in humans. In the current validation study, we established a mouse model of hyperglycemia by administering high levels of glucose to mice.   Here at Melior Discovery, we have established a mouse model of hyperglycemia by administering high levels of glucose to mice. 

              Oral glucose tolerance test OGTT Metformin    

Oral Glucose Tolerance Test.  Blood glucose levels were evaluated thirty minutes prior to dosing (-30 min), immediately post dose (0 minutes) and then 15, 30, 60, 90, 120 and 180 minutes following vehicle or Metformin administration.  The vehicle mice exhibited elevated blood glucose levels throughout the study.  The Metformin treated mice exhibited a reduction in blood glucose levels after glucose challenge.  On Day 1 of the study (A), blood glucose levels in Metformin treated mice were immediately  reduced after dosing compared to vehicle treated mice.  On both, Day 7 and Day 14, additional time passed before blood glucose levels were reduced 15 minutes after dosing (B) and 30 minutes after dosing (C).  Data are mean ± SEM; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 compared to vehicle. 

 

If you are interested in learning more about Oral Glucose Tolerance Test, please contact models@meliordiscovery.com to start the conversation.